whilst this has not been established as a formal contraindication in UK SmPCs for approved GLP-1 receptor agonists, clinical caution and specialist review are warranted for individuals with relevant thyroid or endocrine history [24] [25] Pancreatitis (current or historical), as GLP-1-based therapies have been associated with pancreatic inflammation [19] Type 1 or Type 2 diabetes , particularly if already managed with insulin, sulfonylureas, or other glucose-lowering agents, due to an increased risk of hypoglycaemia Cardiovascular disease , given observed increases in heart rate with retatrutide in trial data Renal or hepatic impairment , as these may affect drug metabolism and tolerability Pregnancy or breastfeeding , as safety data in these populations are entirely absent When to seek urgent medical attention: If, after administration, an individual experiences severe nausea or vomiting, chest pain, rapid or irregular heartbeat, severe abdominal pain, signs of an allergic reaction (such as rash, swelling of the face or throat, or difficulty breathing), or symptoms of hypoglycaemia (such as sweating, shaking, confusion, or loss of consciousness) , they should: Call 999 immediately for life-threatening emergencies Call NHS 111 for urgent medical advice Attend an A&E department as appropriate Transparency with healthcare professionals about the substance used is essential for safe and effective clinical management
Product details Net content: 10 mg per vial Format: Lyophilized material Container: 3 mL glass vial Lot/batch: Recorded on product label where available Intended use Non-clinical laboratory research Analytical reference and assay development within institutional programs Use only in accordance with institutional SOPs and applicable regulatory requirements Not for human or animal consumption Not for clinical, therapeutic, or diagnostic use Certificate of Analysis (COA) For full quality details, please refer to the second image on this page for the Certificate of Analysis (COA) for Cagrilintide Canada 10mg
*All prices are tax exclusive.
Engineering a potent and long-acting GLP-1/Y2 receptor dual agonist as a multi-agonist therapy for diabetes and obesity
